Search research articles
Contact Us
Filters
Showing results (111-120 of 134) with videos related to
Page
of 14
Sort By:
Journal of the National Cancer Institute
|
September 8, 2005
Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17
Paul E Goss, James N Ingle, Silvana Martino, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 12, 2008
Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen
Paul E Goss, James N Ingle, Joseph L Pater, et al.
Breast Cancer Research and Treatment
|
March 17, 2006
Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial
James N Ingle, Dongsheng Tu, Joseph L Pater, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 25, 2007
Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17
Paul E Goss, James N Ingle, Silvana Martino, et al.
Journal of the National Cancer Institute
|
May 1, 2016
Comparing Breast Cancer Multiparameter Tests in the OPTIMA Prelim Trial: No Test Is More Equal Than the Others
John M S Bartlett, Jane Bayani, Andrea Marshall, et al.
Nature
|
December 7, 2021
Multi-omic machine learning predictor of breast cancer therapy response
Stephen-John Sammut, Mireia Crispin-Ortuzar, Suet-Feung Chin, et al.
Breast (Edinburgh, Scotland)
|
June 29, 2026
Tucatinib in patients with HER2-positive advanced/metastatic breast cancer: A systematic literature review of real-world evidence
Rodrigo Sanchez-Bayona, Carey Anders, Rupert Bartsch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 22, 2015
Predicting Anthracycline Benefit: TOP2A and CEP17-Not Only but Also
John M S Bartlett, Christopher C McConkey, Alison F Munro, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 15, 2022
Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
Nigel Bundred, Nuria Porta, Adrian Murray Brunt, et al.
Health Technology Assessment (Winchester, England)
|
September 4, 2020
Six versus 12 months' adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT
Helena Earl, Louise Hiller, Anne-Laure Vallier, et al.
Page
of 14
Search research articles
Search
Showing results (111-120 of 134) with videos related to
Sort By:
Page
of 14
Journal of the National Cancer Institute
|
September 8, 2005
Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17
Paul E Goss, James N Ingle, Silvana Martino, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 12, 2008
Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen
Paul E Goss, James N Ingle, Joseph L Pater, et al.
Breast Cancer Research and Treatment
|
March 17, 2006
Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial
James N Ingle, Dongsheng Tu, Joseph L Pater, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 25, 2007
Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17
Paul E Goss, James N Ingle, Silvana Martino, et al.
Journal of the National Cancer Institute
|
May 1, 2016
Comparing Breast Cancer Multiparameter Tests in the OPTIMA Prelim Trial: No Test Is More Equal Than the Others
John M S Bartlett, Jane Bayani, Andrea Marshall, et al.
Nature
|
December 7, 2021
Multi-omic machine learning predictor of breast cancer therapy response
Stephen-John Sammut, Mireia Crispin-Ortuzar, Suet-Feung Chin, et al.
Breast (Edinburgh, Scotland)
|
June 29, 2026
Tucatinib in patients with HER2-positive advanced/metastatic breast cancer: A systematic literature review of real-world evidence
Rodrigo Sanchez-Bayona, Carey Anders, Rupert Bartsch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 22, 2015
Predicting Anthracycline Benefit: TOP2A and CEP17-Not Only but Also
John M S Bartlett, Christopher C McConkey, Alison F Munro, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 15, 2022
Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
Nigel Bundred, Nuria Porta, Adrian Murray Brunt, et al.
Health Technology Assessment (Winchester, England)
|
September 4, 2020
Six versus 12 months' adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT
Helena Earl, Louise Hiller, Anne-Laure Vallier, et al.
Page
of 14